Pharmacy

Your Article Summary

See Latest Articles

CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves
Cryolife, 10/07/09

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, announced that it has received a Humanitarian Use Device designation from the Food and Drug Administration for its CryoValve SG aortic human heart valve. The HUD designation is the first step in obtaining a Humanitarian Device Exemption for the CryoValve SG aortic human heart valve, which is processed with the Company's proprietary SynerGraft technology. An approved HDE would allow the Company to market the CryoValve SG aortic human heart valve.

Today in Cardiac/Hypertension...keeping you current

Receive free subspecialty "5-minute updates" via email

Novartis receives FDA approval for Valturna®, a single-pill combination of valsartan and aliskiren, to treat high blood pressure
Novartis, 09/18/09

Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for Dyslipidemia
Annals of Internal Medicine, 11/03/09

Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy
Current Medical Research and Opinion, 11/20/09

See All of Cardiac/Hypertension

Today in Drug Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

FDA Approves Gardasil to Prevent Genital Warts in Males. Agency Also Approves Bivalent HPV Vaccine for Girls, Young Women
American Family Physician, 10/22/09

Novartis receives FDA approval for Valturna®, a single-pill combination of valsartan and aliskiren, to treat high blood pressure
Novartis, 09/18/09

Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/10/09

See All of Drug Approvals